MA27574A1 - Forme cristalline - Google Patents

Forme cristalline

Info

Publication number
MA27574A1
MA27574A1 MA28366A MA28366A MA27574A1 MA 27574 A1 MA27574 A1 MA 27574A1 MA 28366 A MA28366 A MA 28366A MA 28366 A MA28366 A MA 28366A MA 27574 A1 MA27574 A1 MA 27574A1
Authority
MA
Morocco
Prior art keywords
crystalline form
ethensulfonamide
chlorothiene
oxopyrrolidine
oxoethyl
Prior art date
Application number
MA28366A
Other languages
English (en)
Inventor
C Dell Orco Philip
Anderson Kelly Henry
Punjabhai Shah Gita
Stphen Watson Nigel
John Young Robert
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27574A1 publication Critical patent/MA27574A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Le (E)-2-(5-chlorothiène-2-yl)-N-{(3S)-1-[(1S)-1-méthyl-2-morpholine-4-yl-2-oxoéthyl]-2-oxopyrrolidine-3-yl}éthènesulfonamide sous une forme essentiellement cristalline, des formulations pharmaceutiques de ce composé, des procédés pour sa préparation, et son utilisation en médecine, en particulier son utilisation dans l'amélioration d'un état clinique pour lequel un inhibiteur du facteur Xa est indiqué.
MA28366A 2002-12-06 2005-06-29 Forme cristalline MA27574A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228533.6A GB0228533D0 (en) 2002-12-06 2002-12-06 Crystalline form

Publications (1)

Publication Number Publication Date
MA27574A1 true MA27574A1 (fr) 2005-10-03

Family

ID=9949229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28366A MA27574A1 (fr) 2002-12-06 2005-06-29 Forme cristalline

Country Status (27)

Country Link
US (1) US7645338B2 (fr)
EP (1) EP1567519B1 (fr)
JP (1) JP4660197B2 (fr)
KR (1) KR20050085328A (fr)
CN (1) CN100378098C (fr)
AR (1) AR042304A1 (fr)
AT (1) ATE373652T1 (fr)
AU (1) AU2003293779B2 (fr)
BR (1) BR0317067A (fr)
CA (1) CA2508699A1 (fr)
CY (1) CY1107011T1 (fr)
DE (1) DE60316467T2 (fr)
DK (1) DK1567519T3 (fr)
ES (1) ES2290541T3 (fr)
GB (1) GB0228533D0 (fr)
IS (1) IS7927A (fr)
MA (1) MA27574A1 (fr)
MX (1) MXPA05006032A (fr)
MY (1) MY139916A (fr)
NO (1) NO20053167L (fr)
NZ (1) NZ540365A (fr)
PL (1) PL377184A1 (fr)
PT (1) PT1567519E (fr)
RU (1) RU2339634C2 (fr)
TW (1) TW200420560A (fr)
WO (1) WO2004052878A2 (fr)
ZA (1) ZA200504384B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76346A (en) * 1994-04-26 1997-08-28 Selectide Corp Factor xa inhibitors
WO1998016523A2 (fr) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Inhibiteurs competitifs du facteur xa
US6281227B1 (en) * 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) * 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6525042B1 (en) * 1997-09-30 2003-02-25 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
AU2001255408A1 (en) * 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors
JP2004505257A (ja) * 2000-07-27 2004-02-19 ゼテティック・インスティチュート 共焦点および近接場顕微鏡技術用多重ソースアレイ
AU2001280979A1 (en) * 2000-08-02 2002-02-13 Captivads, Inc. Interactive advertising and multi-media system with a plurality of mobile platforms
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0127568D0 (en) * 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2004052878A2 (fr) 2004-06-24
JP2006510648A (ja) 2006-03-30
ES2290541T3 (es) 2008-02-16
ZA200504384B (en) 2006-03-29
MY139916A (en) 2009-11-30
HK1083491A1 (en) 2006-07-07
NO20053167L (no) 2005-06-28
ATE373652T1 (de) 2007-10-15
NZ540365A (en) 2008-01-31
KR20050085328A (ko) 2005-08-29
CN100378098C (zh) 2008-04-02
DE60316467T2 (de) 2008-06-12
CY1107011T1 (el) 2012-09-26
PT1567519E (pt) 2007-12-17
WO2004052878A3 (fr) 2004-08-12
PL377184A1 (pl) 2006-01-23
RU2005121262A (ru) 2006-01-20
TW200420560A (en) 2004-10-16
EP1567519B1 (fr) 2007-09-19
US20060124049A1 (en) 2006-06-15
RU2339634C2 (ru) 2008-11-27
AR042304A1 (es) 2005-06-15
DE60316467D1 (en) 2007-10-31
IS7927A (is) 2005-07-01
CA2508699A1 (fr) 2004-06-24
DK1567519T3 (da) 2008-01-28
AU2003293779B2 (en) 2008-01-31
JP4660197B2 (ja) 2011-03-30
CN1745079A (zh) 2006-03-08
GB0228533D0 (en) 2003-01-15
AU2003293779A1 (en) 2004-06-30
US7645338B2 (en) 2010-01-12
EP1567519A2 (fr) 2005-08-31
BR0317067A (pt) 2005-10-25
MXPA05006032A (es) 2005-08-18

Similar Documents

Publication Publication Date Title
Hermann et al. Biologic Width around one‐and two‐piece titanium implants: A histometric evaluation of unloaded nonsubmerged and submerged implants in the canine mandible
Sorel et al. Comparison of bond strength between simple foil mesh and laser-structured base retention brackets
Røynesdal et al. A comparative clinical study of three different endosseous implants in edentulous mandibles.
MA27624A1 (fr) Procede pour realiser une preparation enrobee
ATE345782T1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
EA200000246A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
TNSN03106A1 (fr) Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuse uniforme
JP2005538045A5 (fr)
CA2503211A1 (fr) Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
Potey et al. Coronally advanced flap with and without platelet-rich fibrin in the treatment of multiple adjacent recession defects: A randomized controlled split-mouth trial
Schwarz et al. Influence of frequent clinical probing during the healing phase on healthy peri‐implant soft tissue formed at different titanium implant surfaces: a histomorphometrical study in dogs
JP2006516141A5 (fr)
CA2473203A1 (fr) Composition pharmaceutique orodispersible d'ivabradine
RU2005105302A (ru) Композиция бицифадина
CA2473205A1 (fr) Composition pharmaceutique orodispersible de perindopril
PY0218122A (es) Metodo para el tratamiento del insomnio primario
MA27980A1 (fr) Nouvelle composition
MA27996A1 (fr) Nouvelle composition comprenant la rosiglitazone et un autre agent antidiabetique
EA200801305A1 (ru) Применение циклетанина и других фуропиридинов для лечения гипертензии с преобладанием систолического давления, изолированной систолической гипертензии, повышенного пульсового артериального давления и общей гипертензии
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
ITBO20010418A0 (it) Metodo e dispositivo per preparare le strutture dure dei denti all'applicazione di materiali da restauro odontoiatrici
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
MA27731A1 (fr) Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete
EA200101108A1 (ru) Полиморфные модификации кристаллического цитрата азабицикло[2.2.2]октан-3-амина и их фармацевтические композиции